tage clinical trials," Ms. Powers continued. "In the trials so far, patients who received the DCVax® dendritic cell treatments lived for years longer than patients receiving standard of care (not just weeks or months longer), and without toxicity. Building upon the original discovery of dendritic cells by Dr. Steinman, we are working to make dendritic cell treatments widely available for patients, and believe that such treatments have the potential to become a new standard of care for most cancers."
The Company's broad platform technology for dendritic cell-based vaccines is currently being tested in an ongoing 240-patient Phase II clinical trial for newly diagnosed Glioblastoma multiforme ("GBM") -- the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.
Dr. Maida joined the Company in June, 2011, as Chief Operating Officer ("COO"), bringing more than 20 years' experience in building oncology companies, with expertise in the business, financial, clinical and regulatory aspects of oncology products, as well as the underlying science. Over these two decades, Dr. Maida has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised nearly $200 million in financings for oncology companies. Among these experiences, he served as CEO of CancerVax, an early leader in cancer vaccines. In that role, he raised the company's first $30 million of funding, and was responsible for conducting multi-hundred patient, multi-center clinical trials with the company's cancer vaccines. Prior to joining NORTHWEST BIO, Dr. Maida was serving as Global Head of Oncology for a leading contract research organiz
Page: 1 2 3 4 Related biology technology :1
|SOURCE Northwest Biotherapeutics|
Copyright©2010 PR Newswire.
All rights reserved
. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe2
. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions3
. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner4
. Northwest Biotherapeutics Announces Change and Expansion of Management Team5
. Northwest Biotherapeutics Announces Series of Financing Arrangements6
. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy7
. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe8
. Northwest Biotherapeutics Addresses Recent Market Activity9
. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest10
. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast11
. BioSpace Highlights the Northwests Growing Life Science Region